Abstract
How biomarkers can be used to optimize the clinical development of dendritic cell vaccines in immuno-oncology
Full Text
Sign-in/Register to access full text options
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have